Demant (0RGT) Share Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0RGT Analyst Ratings

Moderate Buy

4 Buy

4 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Demant

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0RGT Stock 12 Month Forecast

Average Price Target

kr353.00

▲(24.30% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Demant in the last 3 months. The average price target is kr353.00 with a high forecast of kr430.00 and a low forecast of kr270.00. The average price target represents a 24.30% change from the last price of kr284.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"194":"kr194","431":"kr431","253.25":"kr253.3","312.5":"kr312.5","371.75":"kr371.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":430,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr430.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":353,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr353.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr270.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[194,253.25,312.5,371.75,431],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,314.2,323.1076923076923,332.0153846153846,340.9230769230769,349.8307692307692,358.73846153846154,367.6461538461538,376.55384615384617,385.46153846153845,394.36923076923074,403.2769230769231,412.18461538461537,421.0923076923077,{"y":430,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,314.2,317.18461538461537,320.16923076923075,323.15384615384613,326.1384615384615,329.1230769230769,332.10769230769233,335.0923076923077,338.0769230769231,341.0615384615385,344.04615384615386,347.03076923076924,350.0153846153846,{"y":353,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,314.2,310.8,307.4,304,300.59999999999997,297.2,293.8,290.4,287,283.6,280.2,276.8,273.4,{"y":270,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":224.745,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":215.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218.563,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":214.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.281,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.972,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248.926,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":274.341,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":289.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":314.2,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr430.00

Average Price Targetkr353.00

Lowest Price Targetkr270.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Veronika Dubajova

Citi

kr325→kr430

Buy

51.41%

Upside

Reiterated

10/29/26

Analysts Conflicted on These Healthcare Names: Demant (Other OTC: WILLF) and Bausch Health Companies (NYSE: BHC)

Charles Weston

RBC Capital

kr220→kr384

Hold

35.21%

Upside

Reiterated

10/26/26

Demant price target raised to DKK 384 from DKK 220 at RBC CapitalDemant price target raised to DKK 384 from DKK 220 at RBC Capital

Susannah Ludwig

Bernstein

kr276→kr322

Hold

13.38%

Upside

Reiterated

10/15/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (NASDAQ: VRTX), Demant (Other OTC: WILLF) and Biomea Fusion (NASDAQ: BMEA)

Richard Felton

Goldman Sachs

kr380→kr405

Buy

42.61%

Upside

Reiterated

10/12/26

Goldman Sachs Sticks to Their Buy Rating for Demant (WILLF)

Hassan Al-Wakeel

Barclays

kr270

Hold

-4.93%

Downside

Reiterated

10/02/26

Barclays Sticks to Their Hold Rating for Demant (WILLF)

Jack Reynolds-Clark

Morgan Stanley

kr296→kr388

Buy

36.62%

Upside

Reiterated

09/02/26

Morgan Stanley Sticks to Their Buy Rating for Demant (WILLF)

Martinien Rula

Jefferies

kr290→kr345

Buy

21.48%

Upside

Reiterated

08/20/26

Jefferies Reaffirms Their Buy Rating on Demant (WILLF)

Unknown Analyst

Danske Bank

Not Ranked

Danske Bank

kr280

Hold

-1.41%

Downside

Downgraded

08/06/26

Demant downgraded to Hold from Buy at Danske BankDemant downgraded to Hold from Buy at Danske Bank

Kavya Deshpande

UBS

kr273→kr284

Hold

0.00%

Upside

Downgraded

07/22/26

Demant downgraded to Neutral from Buy at UBSDemant downgraded to Neutral from Buy at UBS

Falko Friedrichs

Deutsche Bank

kr226→kr258

Hold

-9.15%

Downside

Reiterated

07/06/26

Demant price target raised to DKK 258 from DKK 226 at Deutsche BankDemant price target raised to DKK 258 from DKK 226 at Deutsche Bank

Julien Ouaddour

Bank of America Securities

kr170→kr280

Buy

-1.41%

Downside

Upgraded

06/09/26

Demant upgraded to Buy from Underperform at BofADemant upgraded to Buy from Underperform at BofA

Martin Brenoe

Nordea Markets

kr230

Buy

-19.01%

Downside

Upgraded

02/18/26

Demant upgraded to Buy from Hold at NordeaDemant upgraded to Buy from Hold at Nordea

Andjela Bozinovic

Exane BNP Paribas

Not Ranked

Exane BNP Paribas

kr200

Hold

-29.58%

Downside

Downgraded

02/06/26

Demant downgraded to Neutral from Outperform at BNP ParibasDemant downgraded to Neutral from Outperform at BNP Paribas

David Adlington

J.P. Morgan

kr288→kr250

Buy

-11.97%

Downside

Reiterated

02/04/26

Demant price target lowered to DKK 250 from DKK 288 at JPMorganDemant price target lowered to DKK 250 from DKK 288 at JPMorgan

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Veronika Dubajova

Citi

kr325→kr430

Buy

51.41%

Upside

Reiterated

10/29/26

Analysts Conflicted on These Healthcare Names: Demant (Other OTC: WILLF) and Bausch Health Companies (NYSE: BHC)

Charles Weston

RBC Capital

kr220→kr384

Hold

35.21%

Upside

Reiterated

10/26/26

Demant price target raised to DKK 384 from DKK 220 at RBC CapitalDemant price target raised to DKK 384 from DKK 220 at RBC Capital

Susannah Ludwig

Bernstein

kr276→kr322

Hold

13.38%

Upside

Reiterated

10/15/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (NASDAQ: VRTX), Demant (Other OTC: WILLF) and Biomea Fusion (NASDAQ: BMEA)

Richard Felton

Goldman Sachs

kr380→kr405

Buy

42.61%

Upside

Reiterated

10/12/26

Goldman Sachs Sticks to Their Buy Rating for Demant (WILLF)

Hassan Al-Wakeel

Barclays

kr270

Hold

-4.93%

Downside

Reiterated

10/02/26

Barclays Sticks to Their Hold Rating for Demant (WILLF)

Jack Reynolds-Clark

Morgan Stanley

kr296→kr388

Buy

36.62%

Upside

Reiterated

09/02/26

Morgan Stanley Sticks to Their Buy Rating for Demant (WILLF)

Martinien Rula

Jefferies

kr290→kr345

Buy

21.48%

Upside

Reiterated

08/20/26

Jefferies Reaffirms Their Buy Rating on Demant (WILLF)

Unknown Analyst

Danske Bank

Not Ranked

Danske Bank

kr280

Hold

-1.41%

Downside

Downgraded

08/06/26

Demant downgraded to Hold from Buy at Danske BankDemant downgraded to Hold from Buy at Danske Bank

Kavya Deshpande

UBS

kr273→kr284

Hold

0.00%

Upside

Downgraded

07/22/26

Demant downgraded to Neutral from Buy at UBSDemant downgraded to Neutral from Buy at UBS

Falko Friedrichs

Deutsche Bank

kr226→kr258

Hold

-9.15%

Downside

Reiterated

07/06/26

Demant price target raised to DKK 258 from DKK 226 at Deutsche BankDemant price target raised to DKK 258 from DKK 226 at Deutsche Bank

Julien Ouaddour

Bank of America Securities

kr170→kr280

Buy

-1.41%

Downside

Upgraded

06/09/26

Demant upgraded to Buy from Underperform at BofADemant upgraded to Buy from Underperform at BofA

Martin Brenoe

Nordea Markets

kr230

Buy

-19.01%

Downside

Upgraded

02/18/26

Demant upgraded to Buy from Hold at NordeaDemant upgraded to Buy from Hold at Nordea

Andjela Bozinovic

Exane BNP Paribas

Not Ranked

Exane BNP Paribas

kr200

Hold

-29.58%

Downside

Downgraded

02/06/26

Demant downgraded to Neutral from Outperform at BNP ParibasDemant downgraded to Neutral from Outperform at BNP Paribas

David Adlington

J.P. Morgan

kr288→kr250

Buy

-11.97%

Downside

Reiterated

02/04/26

Demant price target lowered to DKK 250 from DKK 288 at JPMorganDemant price target lowered to DKK 250 from DKK 288 at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ARDXArdelyx

PVLAPalvella Therapeutics

CELCCelcuity

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Demant

3 Months

Richard FeltonGoldman Sachs

Success Rate

6/8 ratings generated profit

Average Return

+11.20%

Copying Richard Felton's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +11.20% per trade.

1 Year

Veronika DubajovaCiti

Success Rate

9/10 ratings generated profit

Average Return

+26.40%

Copying Veronika Dubajova's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +26.40% per trade.

2 Years

Richard FeltonGoldman Sachs

Success Rate

8/8 ratings generated profit

Average Return

+41.11%

Copying Richard Felton's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0RGT Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0RGT has received 9 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 0RGT average Analyst price target in the past 3 months is 353.00.

Each month's total comprises the sum of three months' worth of ratings.

0RGT Financial Forecast

0RGT Earnings Forecast

Next quarter’s earnings estimate for 0RGT is kr7.94 with a range of kr7.23 to kr8.76. The previous quarter’s EPS was kr6.40. 0RGT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0RGT has Performed in-line its overall industry.

0RGT Sales Forecast

Next quarter’s sales forecast for 0RGT is kr13.58B with a range of kr13.00B to kr13.93B. The previous quarter’s sales results were kr12.98B. 0RGT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0RGT has Performed in-line its overall industry.

0RGT Stock Forecast FAQ

What is GB:0RGT’s average 12-month price target, according to analysts?

Based on analyst ratings, Demant A/S’s 12-month average price target is 353.00.

What is GB:0RGT’s upside potential, based on the analysts’ average price target?

Demant A/S has 24.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Demant A/S a Buy, Sell or Hold?

Demant A/S has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 4 hold ratings and 0 sell ratings.

What is Demant A/S’s share price target?

The average share price target for Demant A/S is 353.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr430.00 ,and the lowest forecast is kr270.00. The average share price target represents 24.30% Increase from the current price of kr284.

What do analysts say about Demant A/S?

Demant A/S’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Demant A/S?

To buy shares of GB:0RGT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Demant (0RGT) Share Forecast & Price Target

0RGT Analyst Ratings

0RGT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Demant

0RGT Analyst Recommendation Trends

0RGT Financial Forecast

0RGT Earnings Forecast

0RGT Sales Forecast

0RGT Stock Forecast FAQ

Detailed List of Analyst Forecasts